Cormark upgraded shares of Curaleaf (OTCMKTS:CURLF – Free Report) from a hold rating to a moderate buy rating in a research report released on Monday, Zacks.com reports. Cormark also issued estimates for Curaleaf’s FY2024 earnings at ($0.25) EPS and FY2025 earnings at ($0.18) EPS.
Separately, Needham & Company LLC reaffirmed a buy rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th.
Read Our Latest Stock Report on CURLF
Curaleaf Stock Performance
Curaleaf (OTCMKTS:CURLF – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $342.29 million during the quarter, compared to the consensus estimate of $344.57 million. Curaleaf had a negative net margin of 20.29% and a negative return on equity of 14.43%. Equities research analysts expect that Curaleaf will post -0.21 EPS for the current fiscal year.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
- Five stocks we like better than Curaleaf
- There Are Different Types of Stock To Invest In
- Brinker International’s Price Dip is an Appetizing Entry Point
- What is the Nikkei 225 index?
- 3 Stocks That Could Beat the September Blues
- How to Choose Top Rated Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.